A phase II study of a human anti-PDGFR alpha monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

Author(s):
Wagner, A.J.; Kindler, H.; Gelderblom, H.; Schoffski, P.; Bauer, S.; Hohenberger, P.; Kopp, H.G.; Lopez-Martin, J.A.; Peeters, M.; Reichardt, P.; Qin, A.; Nippgen, J.; Ilaria, R.L.; Rutkowski, P.
Published
2017
Publication type
Article / Letter to editor
gastrointestinal stromal tumorplatelet-derived growth factor receptor alphaIMC-3G3mutationmonoclonal antibody
Date issued
2017-03-31
Language
English
Is part of
Annals of Oncology (2017), Vol. 28, no. 3, p. 541-546
hdl
1887/94721
doi
10.1093/annonc/mdw659